



**HAL**  
open science

# Solving the Challenging Synthesis of Highly Cytotoxic Silver Complexes Bearing Sterically Hindered NHC Ligands with Mechanochemistry

Audrey Beillard, François Quintin, Jeremie Gatignol, Pascal Retailleau, Jean-Luc Renaud, Sylvain Gaillard, Thomas-Xavier Métro, Frédéric Lamaty, Xavier Bantreil

► **To cite this version:**

Audrey Beillard, François Quintin, Jeremie Gatignol, Pascal Retailleau, Jean-Luc Renaud, et al.. Solving the Challenging Synthesis of Highly Cytotoxic Silver Complexes Bearing Sterically Hindered NHC Ligands with Mechanochemistry. 2020. hal-02919846v1

**HAL Id: hal-02919846**

**<https://hal.science/hal-02919846v1>**

Preprint submitted on 12 Nov 2020 (v1), last revised 19 Nov 2020 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Solving the Challenging Synthesis of Highly Cytotoxic Silver Complexes bearing Sterically Hindered NHC Ligands with Mechanochemistry

Audrey Beillard,<sup>a</sup> François Quintin,<sup>a</sup> Jérémie Gatignol,<sup>b</sup> Pascal Retailleau,<sup>c</sup> Jean-Luc Renaud,<sup>b</sup> Sylvain Gaillard,<sup>b,\*</sup> Thomas-Xavier Métro,<sup>a</sup> Frédéric Lamaty<sup>a</sup> and Xavier Bantreil<sup>a,\*</sup>

<sup>a</sup> IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France. E-Mail: [xavier.bantreil@umontpellier.fr](mailto:xavier.bantreil@umontpellier.fr)

<sup>b</sup> Normandie University, LCMT, ENSICAEN, UNICAEN, CNRS, 14000, Caen, France. E-Mail: [sylvain.gaillard@ensicaen.fr](mailto:sylvain.gaillard@ensicaen.fr)


<sup>c</sup> Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Saclay, 1 Avenue de la Terrasse, 91198 Gif-sur-Yvette, France

**Abstract.** The use of ball-mills enabled the straightforward synthesis of a variety of silver(I) complexes featuring challenging NHC ligands. Sterically hindered including electron-poor or with very low solubility imidazolium salts were grinded with silver(I) oxide to furnish heteroleptic or homoleptic complexes in high yield and short reaction times. The synthesis of heteroleptic bis-NHC silver(I) complexes was also performed for the first time in a ball-mill. The efficiency and rapidity of the mechanochemical approach enabled the generation of a library of unprecedented NHC silver complexes, which cytotoxicity on HCT116 colorectal cancer cell line was evaluated providing a rare example of medicinal mechanochemistry. The cationic silver complexes were found more potent than the neutral analogues, with IC<sub>50</sub> values down to 21 nM, 256 times more potent than cisplatin.

*N*-heterocyclic carbenes (NHC) are widely used for the stabilization of transition metals, especially compared to phosphines in catalytic systems.<sup>1</sup> Additionally, NHC-based complexes have found interest due to their biological properties, for example for their antibacterial, antifungal or anticancer properties.<sup>2</sup> Besides, many groups have shown that NHC-gold(I) and NHC-gold(III) complexes could be valid alternatives to cisplatin due to their different mode of action.<sup>3</sup> Silver(I) complexes have also been studied because they might behave similarly to gold complexes.<sup>2a-e, 4</sup> However, NHC-silver(I) complexes have mostly been studied for their antibacterial and antimicrobial activity,<sup>5</sup> and only some of them were found to be active as anticancer agents.<sup>6</sup> However, most of these complexes were either neutral [AgCl(NHC)] complexes or cationic homoleptic [Ag(NHC)<sub>2</sub>] complexes featuring *N,N*-dialkyl ligands. Cationic homoleptic [Ag(NHC)<sub>2</sub>] complexes bearing *N,N*-diaryl NHC ligands have been less studied because their synthesis is known to be more challenging. Yet, we recently developed a mechanochemical<sup>7</sup> solvent-free method that enables a rapid and highly efficient access to such complexes.<sup>8</sup> Additionally, ball-milling permits to easily synthesize neutral [AgCl(NHC)] complexes, either with alkyl or aryl substituents.<sup>9</sup> In this manuscript, we initially focused our attention on

the mechanosynthesis of less conventional silver complexes bearing sterically hindered NHC including one with electron withdrawing groups, to assess if the mechanochemical approach could solve synthetic problems encountered in solution.<sup>7d</sup> Then, we evaluated the cytotoxicity of the corresponding complexes, as well as heteroleptic bis-NHC complexes, as anticancer agents on colorectal HCT116 cancer cell line. Of note, this represents one of the rare examples of mechanochemical synthesis of molecules for biological testing, a branch of medicinal mechanochemistry.<sup>10</sup>

First, the synthesis of neutral heteroleptic complexes was realized by milling highly encumbered imidazolium salts **1a-e** and silver(I) oxide in slight excess in a stainless steel jar containing a 1 cm diameter stainless steel ball, using a vibratory MM400 ball-mill (Scheme 1). Gratifyingly, after 3 h at 30 Hz, full conversion was obtained in all cases. Complexes **2a** and **2b**, featuring ligands IPr<sup>OMe</sup> (1,3-bis(4-methoxy-2,6-diisopropylphenyl)imidazol-2-ylidene) and MeIPr<sup>OMe</sup> (1,3-bis(4-methoxy-2,6-diisopropylphenyl)-4,5-dimethylimidazol-2-ylidene) could be isolated in 81% and 86% yield, respectively. In solution, the use of electron poor <sup>c</sup>IPr·HCl **1c** (1,3-bis(2,6-diisopropylphenyl)-4,5-dichloroimidazolium chloride)




**Scheme 1.** Mechanosynthesis of  $[\text{AgCl}(\text{NHC})]$  complexes bearing highly encumbered NHC ligands

revealed problematic. Indeed, even when full conversion was obtained, isolated yield of corresponding complex **2c** did not exceed 31%.<sup>11</sup> Of note, the same trend was observed in the synthesis of  $[\text{CuCl}(\text{ClIPr})]$ , with 40% being the highest reported isolated yield.<sup>12</sup> Using the ball-mill, full conversion of **1c** was also observed, but, in sharp contrast to the solution, upon treatment, complex **2c** was isolated in an excellent 90% yield. Increased steric hindrance was not a limit to the method as complexes **2d** and **2e**, featuring  $\text{IPr}^{\text{OMe}}$  ([1,3-bis(4-methoxy-2,6-diphenylmethyl)phenyl]imidazol-2-ylidene)<sup>13</sup> and  $\text{IPr}^*$  ([1,3-bis(4-methyl-2,6-diphenylmethyl)phenyl]imidazol-2-ylidene)<sup>14</sup> ligands, were isolated in 89% and 81%, respectively. It is important to highlight that the solvent-free method revealed highly practical in these cases since the imidazolium salts **1d** and **1e** are poorly soluble in organic solvents and water.

We then turned our attention to unprecedented homoleptic  $[\text{Ag}(\text{NHC})_2]\text{PF}_6$  complexes. Imidazolium salts **1a-i** were first converted into their  $\text{PF}_6$  counterpart **3a-i** using either the classical method, which consists in solubilizing the chloride salt in water in the presence of  $\text{KPF}_6$  and recover the hexafluorophosphate salt that precipitates, or our previously reported solvent-free milling approach.<sup>8</sup>


**Table 1.** Comparison of methods for the synthesis of  $[\text{Ag}(\text{ClIPr})_2]\text{PF}_6$ .<sup>a</sup>



Entry	Conditions	t (h)	Conv. (%) <sup>b</sup>
1	CHCl <sub>3</sub> , reflux	24	31
		48	90
2	NaOH (1.1), CH <sub>2</sub> Cl <sub>2</sub> , rt	24	100 (45)
		3	100 (85)


<sup>a</sup> Reaction conditions: **3c** (0.15 mmol, 1 eq.),  $\text{Ag}_2\text{O}$  (0.075 mmol, 0.5 eq.). <sup>b</sup> Conversion determined by <sup>1</sup>H NMR. Isolated yield is given in brackets.

This latter technique enabled the reduction of the quantity of  $\text{KPF}_6$  and water used, and was found to be particularly efficient for salt **1e** that reacts poorly in water due a reduced solubility. In the ball-mill, anion metathesis occurred in 30 min under solvent-free conditions. We first focused on the synthesis of complex **4c**, featuring electron poor  $\text{ClIPr}$  ligand (Table 1). As discussed above, isolation of complexes featuring this ligand is difficult when the reaction is performed in solution. Reaction of **3c** with silver(I) oxide in refluxing chloroform gave only 31% NMR conversion after 24h, and 90% after 48h (Table 1, entry 1). In dichloromethane at room temperature, with the addition of sodium hydroxide, it was possible to obtain full conversion of  $\text{ClIPr} \cdot \text{HPF}_6$  **3c** in 24 h (Table 1, entry 2). However, upon isolation through filtration on Celite® and evaporation, complex **4c** was obtained in only 45% yield. When imidazolium salt **3c** was ball-milled with NaOH and  $\text{Ag}_2\text{O}$  under solvent-free conditions at 30 Hz for 3h, 100% conversion was also observed. More importantly, after the same treatment as when the reaction was performed in solution, homoleptic complex  $[\text{Ag}(\text{ClIPr})_2]\text{PF}_6$  **4c** was isolated in 85% yield (Table 1, entry 3). The desired complex **4c** may thus easily decompose in solution while the solvent-free approach gives a much faster access the complex and in a two-fold higher isolated yield.




**Scheme 2.** Mechanochemical synthesis of homoleptic  $[\text{Ag}(\text{NHC})_2]\text{PF}_6$  complexes bearing highly encumbered NHC ligands

The mechanochemical approach was then applied to salts **3a-e** in the presence of silver oxide and sodium hydroxide (Scheme 2). As for complexes **2a-e**, full conversion was observed in all cases in 3 h of milling. Homoleptic complexes **4a** and **4b** were isolated in excellent yields. The milling method was then applied successfully to poorly soluble  $\text{IPr}^*\text{OMe}.\text{HPF}_6$  **3d**. After 3h




**Figure 1.**  $^{13}\text{C}$  solid state HR-MAS NMR of  $\text{IPr}^*.\text{HPF}_6$  **3e** (red) and  $[\text{Ag}(\text{IPr}^*)_2]\text{PF}_6$  **4e** (blue)



**Scheme 3.** Mechanochemical synthesis of homoleptic  $[\text{Ag}(\text{NHC})_2]\text{PF}_6$  complexes bearing *N*-alkyl, *N*-aryl ligands

of milling at 30 Hz, corresponding  $[\text{Ag}(\text{IPr}^*\text{OMe})_2]\text{PF}_6$  **4d** was isolated in 94% yield. On the other hand,  $[\text{Ag}(\text{IPr}^*)_2]\text{PF}_6$  **4e** revealed highly unstable compared to **4d**, probably because of the worse  $\sigma$ -donation of  $\text{IPr}^*$  compared to  $\text{IPr}^*\text{OMe}$ .<sup>13, 15</sup>  $^1\text{H}$  NMR analysis showed the disappearance of the characteristic C-H proton of the imidazolium salt **3e**, with the formation of corresponding complex **4e**. Due to a quick decomposition of **4e**, it was impossible to obtain  $^{13}\text{C}$  NMR analysis of the pure compound.<sup>16</sup> Nevertheless, solid-state HR-MAS (high resolution magic angle spinning)  $^{13}\text{C}$  NMR spectroscopy on a 600 MHz spectrometer confirmed the formation of the complex with the appearance of the characteristic carbonyl carbon signal of **4e** at 182 ppm (Figure 1). The low stability of  $[\text{Ag}(\text{IPr}^*)_2]\text{PF}_6$  **4e** could explain the low yields when the reactions were performed in solution. Indeed, the best conversion obtained when the reaction was attempted in refluxing chloroform was 62% after 48 h, yet along with important decomposition.<sup>16</sup> Comparatively, complex **4e** was isolated in 93% yield after 3h of milling.

The synthesis of novel homoleptic complexes featuring *N*-alkyl, *N*-aryl ligands was next performed (Scheme 3). Reaction of imidazolium salt **3f**, bearing a mesityl and a 2-picoyl group on the nitrogen atoms, was found to be slightly slower than with *N,N*-diaryl imidazolium




**Scheme 4.** Mechanochemical synthesis of cationic heteroleptic silver complexes

salts **3a-e**, with 79% conversion after 3 h at 30 Hz. Hence, reaction was performed using a planetary ball-mill, which is more adapted to longer reaction times. After 5 h at 450 rpm, full conversion was obtained, yielding complex **4f** in 80%. With a similar ligand bearing a benzyl instead of the 2-picoly group, reaction proceeded efficiently and **4g** was isolated in 97% yield. Increasing the steric hindrance on the aromatic ring with a 2,6-diisopropylphenyl group resulted in slightly lower yields of 70% and 88% for **4h** and **4i**, respectively.

Finally, heteroleptic bis-NHC silver(I) complexes were synthesized using the vibratory ball-mill, starting from [AgCl(IPr)] **2f** (IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene), which was prepared via mechanochemistry.<sup>9a</sup> To the best of our knowledge, the synthesis of heteroleptic silver(I) complexes was never attempted in a ball-mill. Reaction was thus first realized using classical IMes·HPF<sub>6</sub> (1,3-bis(2,4,6-trimethylphenyl)imidazolium) and SIMes·HPF<sub>6</sub> (1,3-bis(2,4,6-trimethylphenyl)imidazolium) salts in the presence of sodium hydroxide (Scheme 4). After 1 h of milling at 30 Hz in a vibratory ball-mill, full conversions were obtained and heteroleptic complexes **5a** and **5b** were isolated in 90% and 91% yield,

respectively. Reaction with <sup>Cl</sup>IPr·HPF<sub>6</sub> **3c** and MeIPr<sup>OMe</sup>·HPF<sub>6</sub> **3b** yielded corresponding complexes **5c** and **5d** in 88% and 89%, respectively. To widen the scope of attainable heteroleptic complexes using this methodology,

*N,N*-dibenzylimidazolium



**Figure 2.** ORTEPs (at 50% probability level) of compounds (a) **2b**, (b) **4a**. Hydrogen atoms and PF<sub>6</sub> anion are omitted for clarity.




**Table 2.** % $V_{bur}$  for the different complexes

Entry	Complex	$d_{C-M}$ (Å)	% $V_{bur}^a$	% $V_{bur}^b$
1	2a	2.080	40.2	41.3
2	2b	2.087	42.8	42.5
3	2e <sup>14</sup>	2.078	52.9	52.9
4	4a	2.099	38.7	38.7
5	4b	2.122	40.2	40.7


<sup>a</sup> % $V_{bur}$  calculated with real C-Ag distance, sphere radius of 3.5 Å. <sup>b</sup> distance C-Ag normalized at 2.1 Å, sphere radius 3.5 Å.

hexafluorophosphate and TPT-HPF<sub>6</sub> (1,3,4-triphenyl-1,2,4-triazolium hexafluorophosphate) were reacted efficiently to furnish **5e** and **5f** in excellent yields. X-ray quality crystals could be grown by slow diffusion of diethyl ether into a dichloromethane solution of complexes **2a**, **2b**, **4a** and **4b** (Figure 2). XRD analysis allowed to evaluate the steric properties of the ligands by calculating the % $V_{Bur}$  (percent buried volume) of each complex using the *SambVca* web application (Table 2).<sup>17</sup> As already witnessed with other metals, the introduction of methyl groups on the NHC backbone (**2a** vs **2b** and **4a** vs **4b**), which push the aromatic moieties towards the metal center, induces an increase in % $V_{Bur}$  in each case. The increase of the sterical hindrance also results in a longer NHC-metal distance. In comparison, ligand IPr\* was found to be extremely hindered as % $V_{Bur}$  calculated for **2e** reaches a value of 52.9 while the % $V_{Bur}$  of the isopropyl analogues do not exceed the value of 42.8.

Since homoleptic silver(I) complexes featuring benzimidazole<sup>6e</sup> or imidazopyridine-based<sup>6f</sup> NHC ligand have already shown promising activity against colorectal HCT116 cancer cell lines compared to 5-fluorouracil or cisplatin, respectively, the unique capacity of mechanochemistry to generate rapidly a library of NHC silver complexes (**2a-5f**) prompted us to evaluate their cytotoxicity against this cell line.<sup>16</sup> The percentage inhibition of cell proliferation was firstly measured using 10<sup>-5</sup> and 10<sup>-6</sup> M solutions of the complexes (Figure 3). Half growth inhibition concentration (IC<sub>50</sub>) was then measured only for compounds that showed high % of inhibition at 10<sup>-6</sup> M (Figure 4). As a comparison, doxorubicin and cisplatin, which are commonly used to treat cancer, were evaluated on the same cancer cell line and possess IC<sub>50</sub> of 810 nM and 5.37 μM, respectively. In addition, [AgClIPr] **2f** and [Ag(IPr)<sub>2</sub>]PF<sub>6</sub> **4j** complexes were also tested to evaluate the influence of substitutions of the

**Figure 3.** Percentage of inhibition against HCT116 carcinoma cells at 10<sup>-5</sup> and 10<sup>-6</sup> M

ligand on cytotoxicity. Among the neutral heteroleptic complexes **2a-f**, only **2d** and **2e** were found almost inactive. Such behavior could be assigned to the poor solubility of the complexes in DMSO. Complex **2a** showed an IC<sub>50</sub> of 259 nM. As a comparison, **2f**, which contains the classical IPr ligand, exhibited an IC<sub>50</sub> of 390 nM, thus showing the positive influence of the methoxy groups on the NHC. The introduction of methyl group on the backbone of the NHC resulted in another positive effect as **2b** was found to be active at 96.8 nM. On the other hand, **2c**, featuring chlorine atoms on the backbone of the NHC, displayed an IC<sub>50</sub> of 616 nM. Cationic homoleptic complexes having *N,N*-diaryl NHC ligands **4a-c** displayed a higher cytotoxicity, with IC<sub>50</sub> values down to 24.9 nM for **4b**. Once again, the positive effect of the methoxy group

**Figure 4.** IC<sub>50</sub> (nM) values against HCT116 carcinoma cells

was demonstrated as [Ag(IPr)<sub>2</sub>]PF<sub>6</sub> complex displayed on IC<sub>50</sub> of 140 nM (35.4 nM for **4a**). The addition of methyl groups on the NHC backbone results in even lower IC<sub>50</sub> value (35.4 nM for **4a** vs 24.9 nM for **4b**). Homoleptic complexes **4f-i**, containing *N*-aryl, *N*-alkyl NHC ligands, were found to be less active. In this family, **4h** was the most active, with an IC<sub>50</sub> at 293 nM. Cationic bis-NHC silver complexes **5a-f** also showed promising activity. **5a**, featuring an IMes ligand, was more cytotoxic than **5b** that contains the analogous saturated ligand. While very similar in structure, **5d**, having one IPr ligand in place of MeIPr<sup>OMe</sup>, was found to be slightly more active than homoleptic **4b**, with the best IC<sub>50</sub> of 21 nM. **4b** is thus 256 and 38 times more active than cisplatin and doxorubicin, respectively. Interestingly, **5f**, containing a TPT ligand, showed an IC<sub>50</sub> of 163 nM, thus demonstrating a possible diversification of the structure of the active complexes. On the other hand, **5c** and **5e**, featuring a <sup>c</sup>IPr and a *N,N*-dibenzyl NHC ligand, respectively, were not as active, with a % inhibition of cell proliferation below the values obtained for the other complexes. Thus, this preliminary study shows that introducing chlorine atoms on the backbone of the NHC, or using *N*-alkyl, *N*-aryl NHC ligands is detrimental to the biological activity. On the other hand, the MeIPr<sup>OMe</sup> ligand, either in neutral heteroleptic or cationic complexes, seems to present the best positive effect on the cytotoxicity of the silver complexes. Of note, apart from **4g**, all the silver complexes tested displayed a higher cytotoxicity than doxorubicin and cisplatin.

In conclusion, Mechanochemistry overcame solution-based chemistry, permitting to access rapidly and efficiently novel families of neutral heteroleptic and cationic homo- and heteroleptic complexes featuring NHC ligands bearing sterically hindering groups, and also electron-donating or -withdrawing substituents. Importantly, the use of ball-mills enabled the isolation of complexes difficult if not impossible to prepare and isolate using solution-based strategy. As preliminary results, the silver complexes showed high cytotoxic activity against colorectal HCT116 cancer cell line, with IC<sub>50</sub> down to 21 nM, which is 256 times better than cisplatin.

## Acknowledgements

The Université de Montpellier, Centre Nationale de la Recherche Scientifique (CNRS) and Agence Nationale de la Recherche (grant no. ANR-16-CE07-0009-01) are acknowledged for funding.

## References

- (1) (a) Díez-González, S.; Marion, N.; Nolan, S. P. *Chem. Rev.* **2009**, *109*, 3612-3676. (b) Lin, J. C. Y.; Huang, R. T. W.; Lee, C. S.; Bhattacharyya, A.; Hwang, W. S.; Lin, I. J. B. *Chem. Rev.* **2009**, *109*, 3561-3598.
- (2) (a) Oehninger, L.; Rubbiani, R.; Ott, I. *Dalton Trans.* **2013**, *42*, 3269-3284. (b) Liu, W.; Gust, R. *Chem. Soc. Rev.* **2013**, *42*, 755-773. (c) Gautier, A.; Cisnetti, F. *Metallomics* **2012**, *4*, 23-32. (d) Mercks, L.; Albrecht, M. *Chem. Soc. Rev.* **2010**, *39*, 1903-1912. (e) Teyssot, M.-L.; Jarrousse, A.-S.; Manin, M.; Chevry, A.; Roche, S.; Norre, F.; Beaudoin, C.; Morel, L.; Boyer, D.; Mahiou, R.; Gautier, A. *Dalton Trans.* **2009**, 6894-6902. (f) Liu, W.; Gust, R. *Coord. Chem. Rev.* **2016**, *329*, 191-213. (g) Hu, C.; Li, X.; Wang, W.; Zhang, R.; Deng, L. *Curr. Med. Chem.* **2014**, *21*, 1220-1230.
- (3) (a) Zou, T.; Lum, C. T.; Lok, C.-N.; Zhang, J.-J.; Che, C.-M. *Chem. Soc. Rev.* **2015**, *44*, 8786-8801. (b) Bertrand, B.; Casini, A. *Dalton Trans.* **2014**, *43*, 4209-4219. (c) Cisnetti, F.; Gautier, A. *Angew. Chem. Int. Ed.* **2013**, *52*, 11976-11978. (d) Rieb, J.; Dominelli, B.; Mayer, D.; Jandl, C.; Drechsel, J.; Heydenreuter, W.; Sieber, S. A.; Kuehn, F. E. *Dalton Trans.* **2017**, *46*, 2722-2735. (e) Mora, M.; Gimeno, M. C.; Visbal, R. *Chem. Soc. Rev.* **2019**, *48*, 447-462. (f) Porchia, M.; Pellei, M.; Marinelli, M.; Tisato, F.; Del Bello, F.; Santini, C. *Eur. J. Med. Chem.* **2018**, *146*, 709-746.
- (4) (a) Aher, S. B.; Muskawar, P. N.; Thenmozhi, K.; Bhagat, P. R. *Eur. J. Med. Chem.* **2014**, *81*, 408-419. (b) Hussaini, S. Y.; Haque, R. A.; Razali, M. R. *J. Organomet. Chem.* **2019**, *882*, 96-111. (c) Johnson, N. A.; Southerland, M. R.; Youngs, W. J. *Molecules* **2017**, *22*, 1263/1-1263/20. (d) Mohamed, H. A.; Willans, C. E. *Organomet. Chem.* **2014**, *39*, 26-50.
- (5) (a) Mottais, A.; Berchel, M.; Le Gall, T.; Sibiril, Y.; d'Arbonneau, F.; Laurent, V.; Jaffres, P.-A.; Montier, T. *Int. J. Pharm.* **2019**, *567*, 118500. (b) Boubakri, L.; Dridi, K.; Al-Ayed, A. S.; Ozdemir, I.; Yasar, S.; Hamdi, N. *J. Coord. Chem.* **2019**, *72*, 2080-2090.
- (6) (a) Sahin-Bolukbasi, S.; Sahin, N. *J. Organomet. Chem.* **2019**, *891*, 78-84. (b) Marinelli, M.; Santini, C.; Pellei, M. *Curr. Top. Med. Chem.* **2016**, *16*, 2995-3017. (c) Budagumpi, S.; Haque, R. A.; Endud, S.; Rehman, G. U.; Salman, A. W. *Eur. J. Inorg. Chem.* **2013**, 4367-4388. (d) Eloy, L.; Jarrousse, A.-S.; Teyssot, M.-L.; Gautier, A.; Morel, L.; Jolival, C.; Cresteil, T.; Roland, S.

- ChemMedChem* **2012**, *7*, 805-814. (e) Haque, R. A.; Choo, S. Y.; Budagumpi, S.; Iqbal, M. A.; Al-Ashraf Abdullah, A. *Eur. J. Med. Chem.* **2015**, *90*, 82-92. (f) Jhulki, L.; Dutta, P.; Santra, M. K.; Cardoso, M. H.; Oshiro, K. G. N.; Franco, O. L.; Bertolasi, V.; Isab, A. A.; Bielawski, C. W.; Dinda, J. *New J. Chem.* **2018**, *42*, 13948-13956. (g) Iqbal, M. A.; Haque, R. A.; Budagumpi, S.; Khadeer Ahamed, M. B.; Abdul Majid, A. M. S. *Inorg. Chem. Commun.* **2013**, *28*, 64-69. (h) Iqbal, M. A.; Haque, R. A.; Ahamed, M. B. K.; Majid, A. M. S. A.; Al-Rawi, S. S. *Med. Chem. Res.* **2013**, *22*, 2455-2466. (i) Asif, M.; Iqbal, M. A.; Hussein, M. A.; Oon, C. E.; Haque, R. A.; Khadeer Ahamed, M. B.; Abdul Majid, A. S.; Abdul Majid, A. M. S. *Eur. J. Med. Chem.* **2016**, *108*, 177-187.
- (7) (a) Beillard, A.; Bantreil, X.; Métro, T.-X.; Martinez, J.; Lamaty, F. *Chem. Rev.* **2019**, *119*, 7529-7609. (b) Howard, J.; Cao, Q.; Browne, D. L. *Chem. Sci.* **2018**, *9*, 3080-3094. (c) Andersen, J.; Mack, J. *Green Chem.* **2018**, *20*, 1435-1443. (d) Hernández, J. G.; Bolm, C. *J. Org. Chem.* **2017**, *82*, 4007-4019. (e) Do, J.-L.; Frišćić, T. *ACS Central Science* **2017**, *3*, 13-19. (f) Rightmire, N. R.; Hanusa, T. P. *Dalton Trans.* **2016**, *45*, 2352-2362. (g) Hernández, J. G.; Frišćić, T. *Tetrahedron Lett.* **2015**, *56*, 4253-4265. (h) Wang, G.-W. *Chem. Soc. Rev.* **2013**, *42*, 7668-7700. (i) Takacs, L. *Chem. Soc. Rev.* **2013**, *42*, 7649-7659. (j) James, S. L.; Adams, C. J.; Bolm, C.; Braga, D.; Collier, P.; Frišćić, T.; Grepioni, F.; Harris, K. D. M.; Hyett, G.; Jones, W.; Krebs, A.; Mack, J.; Maini, L.; Orpen, A. G.; Parkin, I. P.; Shearouse, W. C.; Steed, J. W.; Waddell, D. C. *Chem. Soc. Rev.* **2012**, *41*, 413-447.
- (8) Beillard, A.; Bantreil, X.; Métro, T.-X.; Martinez, J.; Lamaty, F. *Dalton Trans.* **2016**, *45*, 17859-17866.
- (9) (a) Beillard, A.; Bantreil, X.; Métro, T.-X.; Martinez, J.; Lamaty, F. *New J. Chem.* **2017**, *41*, 1057-1063. (b) Beillard, A.; Golliard, E.; Gillet, V.; Bantreil, X.; Métro, T.-X.; Martinez, J.; Lamaty, F. *Chem. Eur. J.* **2015**, *21*, 17614-17617.
- (10) (a) Chakraborty, B. *J. Heterocycl. Chem.* **2019**. (b) Oliveira, P. F. M.; Guidetti, B.; Chamayou, A.; André-Barrès, C.; Madacki, J.; Korduláková, J.; Mori, G.; Orena, B. S.; Chiarelli, L. R.; Pasca, M. R.; Lherbet, C.; Carayon, C.; Massou, S.; Baron, M.; Baltas, M. *Molecules* **2017**, *22*, 1457. (c) Tirapegui, C.; Acevedo-Fuentes, W.; Dahech, P.; Torrent, C.; Barrias, P.; Rojas-Poblete, M.; Mascayano, C. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 1649-1653. (d) Tan, D.; Loots, L.; Friscic, T. *Chem. Commun.* **2016**, *52*, 7760-7781.
- (11) Gaillard, S.; Slawin, A. M. Z.; Bonura, A. T.; Stevens, E. D.; Nolan, S. P. *Organometallics* **2010**, *29*, 394-402.
- (12) Elie, M.; Sguerra, F.; Di Meo, F.; Weber, M. D.; Marion, R.; Grimault, A.; Lohier, J.-F.; Stallivieri, A.; Brosseau, A.; Pansu, R. B.; Renaud, J.-L.; Linares, M.; Hamel, M.; Costa, R. D.; Gaillard, S. *ACS Appl. Mater. Interfaces* **2016**, *8*, 14678-14691.
- (13) Meiries, S.; Speck, K.; Cordes, D. B.; Slawin, A. M. Z.; Nolan, S. P. *Organometallics* **2013**, *32*, 330-339.
- (14) Berthon-Gelloz, G.; Siegler, M. A.; Spek, A. L.; Tinant, B.; Reek, J. N. H.; Marko, I. E. *Dalton Trans.* **2010**, *39*, 1444-1446.
- (15) (a) Nelson, D. J.; Collado, A.; Manzini, S.; Meiries, S.; Slawin, A. M. Z.; Cordes, D. B.; Nolan, S. P. *Organometallics* **2014**, *33*, 2048-2058. (b) Huynh, H. V. *Chem. Rev.* **2018**, *118*, 9457-9492.
- (16) See Supporting Information for details.
- (17) (a) Poater, A.; Cosenza, B.; Correa, A.; Giudice, S.; Ragone, F.; Scarano, V.; Cavallo, L. *Eur. J. Inorg. Chem.* **2009**, 1759-1766. (b) Clavier, H.; Correa, A.; Cavallo, L.; Escudero-Adán, E. C.; Benet-Buchholz, J.; Slawin, A. M. Z.; Nolan, S. P. *Eur. J. Inorg. Chem.* **2009**, *2009*, 1767-1773. (c) Clavier, H.; Nolan, S. P. *Chem. Commun.* **2010**, *46*, 841-861.